I-BET151 (GSK1210151A)

Catalog No.S2780

I-BET151 (GSK1210151A) Chemical Structure

Molecular Weight(MW): 415.44

I-BET151 (GSK1210151A) is a novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 170 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • OVTOKO and OVCA420 cells were treated with DMSO, JQ1 (1 μM) or I-BET151 (1 μM). Cell lysates were immunoblotted with indicated antibodies.

    Theranostics, 2016, 6(2):219-30.. I-BET151 (GSK1210151A) purchased from Selleck.

    B. Western blot analysis of pERK and ERK in cells treated with JQ1 or I-BET151.

    Oncotarget, 2016, 7(3):2545-54. I-BET151 (GSK1210151A) purchased from Selleck.

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description I-BET151 (GSK1210151A) is a novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM in cell-free assays, respectively.
Features Optimized to retain excellent BET target potency and selectivity while enhancing the in vivo pharmacokinetics and terminal half-life to enable prolonged in vivo studies.
Targets
BRD3 [1]
(Cell-free assay)
BRD2 [1]
(Cell-free assay)
BRD4 [1]
(Cell-free assay)
0.25 μM 0.5 μM 0.79 μM
In vitro

I-BET151 exhibits potent selectivity over an extensive range of diverse protein types such as COX-2, P450, Aurora B, GSK3β, PI3K-γ, GPCR, ion channels, and transporters. Similar to I-BET762 (GSK525762A), I-BET151 displays potent binding affinity to BRD2, BRD3 and BRD4 with KD of 0.02-0.1 μM, and significantly inhibits lipopolysaccharide-stimulated IL-6 cytokine production in human peripheral blood mononuclear cells (PBMC) and whole blood (WB) as well as rat WB with IC50 of 0.16 μM, 1.26 μM, and 1.26 μM, respectively. I-BET151 (0.5 or 5 μM) inhibits the binding of BETs (BRD2, BRD3, BRD4, and BRD9) but not the binding of 23 other bromodomain proteins in HL60 nuclear extract to acetylated histone peptides. I-BET151 has potent efficacy against cell lines harboring different MLL-fusions such as MV4;11, RS4;11, MOLM13, and NOMO1 cells with IC50 of 15-192 nM. Consistently, I-BET151 completely ablates the colony-forming potential of MLL-fusion-driven leukaemias (MOLM13) but not leukaemias driven by tyrosine kinase activation (K562). I-BET151 also displays potent efficacy in both liquid culture and clonogenic assays using primary murine progenitors transformed with either MLL-ENL or MLL-AF9. I-BET151 treatment significantly induces apoptosis and prominent G0/G1 arrest in MLL-fusion cell lines driven by distinct MLL fusions (MOLM13 and MV4;11 containing MLL-AF9 and MLL-AF4, respectively) but not the K562 cells, probably due to the inhibition of transcription of BCL2, C-MYC and CDK6 by blocking the recruitment of BRD3/4, PAFc and SEC components into transcriptional start site (TSS). [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV4;11 NHzGTnpkgXSxdH;4bYNqfHliYYPzZZk> MYn+NVAxKM7:TR?= MkfGSG1UVw>? M1vjdWlEPTB;Mk[gcm0> NEe5ZpEzOTl4NEO0NC=>
RS4;11 NVfafnU{[3m2b4TvfIlkcXS7IHHzd4F6 MlzqglExOCEQvF2= M4X3N2ROW09? NH3YOolKSzVyPUG5NkBvVQ>? NGHGOJkzOTl4NEO0NC=>
MOLM13 MWrjfZRwfG:6aXPpeJkh[XO|YYm= NVTofVdrhjFyMDFOwG0> MnjGSG1UVw>? MnrFTWM2OD1zMkCgcm0> NHr6VlIzOTl4NEO0NC=>
NOMO1 M3mzRoN6fG:2b4jpZ4l1gSCjc4PhfS=> NF7TVWZ,OTByIN88US=> MnKwSG1UVw>? NGXafY1KSzVyPUG1JI5O MVmyNVk3PDN2MB?=
HEL M1zhXoN6fG:2b4jpZ4l1gSCjc4PhfS=> NXjk[lFlhjFyMDFOwG0> Ml61SG1UVw>? NVzvNVZDUUN3ME2xJO69VQ>? M4HY[lIyQTZ2M{Sw
K562 MmDyZ5l1d3SxeHnjbZR6KGG|c3H5 M3\abp4yODBizszN M4n6b2ROW09? NV22RYVlUUN3ME6xNFAh|ryP M4TFN|IyQTZ2M{Sw
MEG01 NYDLSoNO[3m2b4TvfIlkcXS7IHHzd4F6 NHr5W|F,OTByIN88US=> M1TBcWROW09? NXHPcoV1UUN3ME2yOUDPxE1? NXTLVJNtOjF7NkSzOFA>
HL60 NFjseZdkgXSxdH;4bYNqfHliYYPzZZk> M{HseJ4yODBizszN NGLwR5VFVVOR NXi2TlIxUUN3ME24PVAhdk1? Mn\6NlE6PjR|NEC=
MV4;11 NYLQT2VpSXCxcITvd4l{KGG|c3H5 MYj+NVAxKM7:TR?= M4Pne2ROW09? M4P5Volv\HWlZYOgZZBweHSxc3nz MV:yNVk3PDN2MB?=
MOLM13 MUPBdI9xfG:|aYOgZZN{[Xl? NGHRTVN,OTByIN88US=> NGLw[otFVVOR MVHpcoR2[2W|IHHwc5B1d3Orcx?= MYqyNVk3PDN2MB?=
MV4;11 MXPGeY5kfGmxbjDhd5NigQ>? M1XlbmROW09? Mn7G[IVkemWjc3XzJJRp\SC{ZXPyeYl1dWWwdDDv[kBDWkR|L{SgZY5lKGmvcHHpdoVlKHKnY4L1bZRu\W62IH;mJGNFUzliYX7kJHBCTjFidH:geIhmKHS{YX7zZ5JqeHSrb37hcEB{fGG{dDDzbZRm MWqyNVk3PDN2MB?=
PBMC Mnz1SpVv[3Srb36gZZN{[Xl? NInEdW1FVVOR MWnpcohq[mm2czDJUE03KHerdHigdGlEPTBib3[gOk44 NFz4[pczOjR|N{GxOS=>
A2 Mm[4SpVv[3Srb36gZZN{[Xl? MoHvglExKM7:TR?= MUjEUXNQ NI\JXlFz\WGldHn2ZZRmeyCuYYTlcpQhUEmYLUG= MmnMNlMzPTV{MUi=
A72 NEPGPGVHfW6ldHnvckBie3OjeR?= M{fKUJ4yOCEQvF2= NHPkSXBFVVOR NHfHfZBz\WGldHn2ZZRmeyCuYYTlcpQhUEmYLUG= NV[3NodSOjN{NUWyNVg>
BC1 NHvl[IpIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NH;EbI9,OSEQvF2= NXXC[Hc{TE2VTx?= NHnGUldKSzVyPUKyNEBvVQ>? NUe3OXdPOjN5OUK0OFg>
BC3 MlTmS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MmTnglEh|ryP M2\MXGROW09? NIDtd2ZKSzVyPUS2NEBvVQ>? MUmyN|c6OjR2OB?=
BCBL1 MYfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NXjpbZRKhjFizszN NHjXcFlFVVOR MYnJR|UxRTN|MDDuUS=> MVOyN|c6OjR2OB?=
BJAB M3L1cWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MnL3glEh|ryP MVnEUXNQ MULJR|UxRTl5MDDuUS=> NV\wN5J7OjN5OUK0OFg>
Namalwa Mo\RS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NH3LRox,OSEQvF2= M4TR[WROW09? MkLlTWM2OD17N{Cgcm0> M{LC[FI{Pzl{NES4
Jurkat MYPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MUD+NUDPxE1? NH:yeVdFVVOR MWHJR|UxRTF{MkCgcm0> MWOyN|c6OjR2OB?=
MM1S MoriS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MWH+NUDPxE1? M3OwbGROW09? NIHDXWhKSzVyPUe2NEBvVQ>? NVWyNXdMOjN5OUK0OFg>
U266 MoDGS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MnXiglEh|ryP M2X0bWROW09? NV[5[odEUUN3ME25OVAhdk1? M{fzc|I{Pzl{NES4
UM-PEL-1 NWfYR4p3T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NVvzeYZNhjFizszN MUPEUXNQ MlPhTWM2OD1{MUCgcm0> Ml3xNlM4QTJ2NEi=
UM-PEL-3 M{DhSGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MVj+NUDPxE1? MVfEUXNQ NVzCOm9CUUN3ME2xPFAhdk1? NFT4OlQzOzd7MkS0PC=>
BC1 MV\GeY5kfGmxbjDhd5NigQ>? MW[1NFAhdk1? NUXxeJpkTE2VTx?= NVTyW3pFcW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeC=> NFrVfY8zOzd7MkS0PC=>
BC3 MUHGeY5kfGmxbjDhd5NigQ>? MWK1NFAhdk1? NYPkWZZwTE2VTx?= M{\JTIlv\HWlZYOgZ4VtdC2leXPs[UBienKnc4S= NWLL[lNqOjN5OUK0OFg>
BC1 M{DEUGZ2dmO2aX;uJIF{e2G7 M{\QVVgxOCCwTR?= Mn\PSG1UVw>? NFL1TlRz\WS3Y3XzJIMuVXmlIIDyc5RmcW5ibHX2[Yx{ NV71fGxjOjN5OUK0OFg>
BC3 NGfNWFdHfW6ldHnvckBie3OjeR?= NELMbnA5ODBibl2= MVjEUXNQ MX7y[YR2[2W|IHOtUZlkKHC{b4TlbY4hdGW4ZXzz MlnzNlM4QTJ2NEi=
H929 NH36T5RHfW6ldHnvckBie3OjeR?= NEDpSol,OSEQvF2= NUjlNZc2TE2VTx?= M3yw[olv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= MlzJNlQ{OzV2OUm=
KMS12PE NIDPd45HfW6ldHnvckBie3OjeR?= NYr4OodyhjFizszN NGLUelFFVVOR MkSwbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= MWiyOFM{PTR7OR?=
KMS12BM M{PHVmZ2dmO2aX;uJIF{e2G7 MnnKglEh|ryP M1LFc2ROW09? NYnkTZNIcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> MV2yOFM{PTR7OR?=
KMS18 M2TIRmZ2dmO2aX;uJIF{e2G7 M{jldZ4yKM7:TR?= M2j1TmROW09? MmCybY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= M1Px[|I1OzN3NEm5
KMS11 M3;scGZ2dmO2aX;uJIF{e2G7 M1XP[Z4yKM7:TR?= MVPEUXNQ NFTacpNqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0 MmK0NlQ{OzV2OUm=
RPMI8226 MUXGeY5kfGmxbjDhd5NigQ>? M37BRZ4yKM7:TR?= MmOwSG1UVw>? MonDbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= Mmr3NlQ{OzV2OUm=
H929 NILVeZVCeG:ydH;zbZMh[XO|YYm= NYX3THkyhjFizszN NH7mOoVFVVOR NV;UbGRRcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NX;Fe|MyOjR|M{W0PVk>
KMS12PE MXnBdI9xfG:|aYOgZZN{[Xl? NVTpdJE5hjFizszN M3zkb2ROW09? NUnLSVVQcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NHzsPGQzPDN|NUS5PS=>
KMS12BM MmLERZBweHSxc3nzJIF{e2G7 NV7ZT2xRhjFizszN MV;EUXNQ NEDSbppqdmS3Y3XzJINmdGxiYYDvdJRwe2m| M4juWFI1OzN3NEm5
KMS18 Mmn4RZBweHSxc3nzJIF{e2G7 NGnW[2R,OSEQvF2= NYnBUHZXTE2VTx?= NHfBOWRqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NIm1dpIzPDN|NUS5PS=>
KMS11 MnPXRZBweHSxc3nzJIF{e2G7 NWLTSoNxhjFizszN NVe1ToZLTE2VTx?= NW\XUVZ3cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MXqyOFM{PTR7OR?=
RPMI8226 MmqxRZBweHSxc3nzJIF{e2G7 MUD+NUDPxE1? NWW5TVlYTE2VTx?= MWDpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NFPNUYgzPDN|NUS5PS=>
U87MG M3\BNmZ2dmO2aX;uJIF{e2G7 Ml7TglExKM7:TR?= NEPFd2NFVVOR MWLy[YR2[2W|IGW4O21IKGOnbHz1cIFzKEGWUDD3bZRpKEmFNUCgc4YhOS5yNTFOwG0> MV:yOFQ6PjN6MR?=
A172 M4q5T2Z2dmO2aX;uJIF{e2G7 M2\MNp4yOCEQvF2= NXTpOHhbTE2VTx?= NFrH[3Nz\WS3Y3XzJINmdGy3bHHyJGFVWCC5aYToJGlEPTBib3[gNU4zQCEQvF2= MmKwNlQ1QTZ|OEG=
SW1783 NXPkZYpoTnWwY4Tpc44h[XO|YYm= NEL1Wlh,OTBizszN MmjzSG1UVw>? MlyxdoVlfWOnczDj[YxtfWyjcjDBWHAhf2m2aDDJR|UxKG:oIEKuOlgh|ryP NIWxe|IzPDR7NkO4NS=>
U87MG MnHTSpVv[3Srb36gZZN{[Xl? MXP+NVAh|ryP NXrTRoNKTE2VTx?= MUnpcoNz\WG|ZYOgdJJweG:{dHnvckBw\iClZXzsd{BqdiC2aHWgS|EwWyC2cnHud4l1cW:w M4nYbFI1PDl4M{ix
RAW267.4 NUPzVnhbTnWwY4Tpc44h[XO|YYm= NV3pb4tFOSEQvF2= NE\VTWVFVVOR NHrmXYZz\WS3Y3XzJGlNNTZicILv[JVkfGmxbjDpcoR2[2WmIHL5JGxRWw>? NYK4eWJTOjR6NUmwNFg>
RAW267.4 NWK5NnQ6TnWwY4Tpc44h[XO|YYm= NIDUZpUyKM7:TR?= MofBSG1UVw>? Mlj1doVlfWOnczD0bIUh[XO|b3PpZZRqd25iYnX0e4VmdiCEUlS0JIFv\CCjY3X0fYxifGWmIIC2OS=> NX\UV2dTOjR6NUmwNFg>
Me007 M2jXOGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M{XiUJ4yODBizszN NU\6Z5ZwTE2VTx?= NX\iPGlxcW6qaXLpeJMhfGinIHfyc5d1cA>? NGG4UmUzPDlyNkGzOy=>
SK-Mel-28 NYfpWYlJT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NFrGfpZ,OTByIN88US=> NEDDblFFVVOR M4n4dIlvcGmkaYTzJJRp\SCpcn;3eIg> NHzhbXczPDlyNkGzOy=>
Mel-RMU NWHDeZRFT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MlHOglExOCEQvF2= NF;ZfmRFVVOR MWnpcohq[mm2czD0bIUh\3Kxd4To MYmyOFkxPjF|Nx?=
Mel-JD MoLlS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MVL+NVAxKM7:TR?= NH70V|VFVVOR NWe3NY5CcW6qaXLpeJMhfGinIHfyc5d1cA>? MnHDNlQ6ODZzM{e=
Mel-RM MXzHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MnftglExOCEQvF2= NYjLRYZXTE2VTx?= NYTTUmhlcW6qaXLpeJMhfGinIHfyc5d1cA>? NVTieGZVOjR7ME[xN|c>
Me007 Ml:1RZBweHSxc3nzJIF{e2G7 M2GzZp4yODBizszN MVHEUXNQ MnnZbY5lfWOnczDhdI9xfG:|aYO= MWeyOFkxPjF|Nx?=
SK-Mel-28 NUe0eZkzSXCxcITvd4l{KGG|c3H5 NWLtToFohjFyMDFOwG0> NX;nU3A{TE2VTx?= MlrxbY5lfWOnczDhdI9xfG:|aYO= NUX3T|lZOjR7ME[xN|c>
Mel-RMU MlX3RZBweHSxc3nzJIF{e2G7 NFHSSZp,OTByIN88US=> NGfXXVlFVVOR NYOyZ4RncW6mdXPld{BieG:ydH;zbZM> NVHYOZliOjR7ME[xN|c>
Mel-JD NVzYPFd[SXCxcITvd4l{KGG|c3H5 NEXCNHB,OTByIN88US=> M1LtTGROW09? NXLxXot{cW6mdXPld{BieG:ydH;zbZM> NIX3[YgzPDlyNkGzOy=>
Mel-RM NXLNRpdGSXCxcITvd4l{KGG|c3H5 NVfISopNhjFyMDFOwG0> MoixSG1UVw>? NIXjNYJqdmS3Y3XzJIFxd3C2b4Ppdy=> NUTFd5NOOjR7ME[xN|c>
Me007 NHXPTXdHfW6ldHnvckBie3OjeR?= MnnBNVAh|ryP M1;YZWROW09? NF7uS2FqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIJ6KHWycnXneYxifGmxbjDv[kBxOjF? NXf3VYxvOjR7ME[xN|c>
SK-Mel-28 MlLRSpVv[3Srb36gZZN{[Xl? NVnmU5VkOTBizszN M{L5SmROW09? M3nOXIlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZpkhfXC{ZXf1cIF1cW:wIH;mJJAzOQ>? NXzlOXlHOjR7ME[xN|c>
Mel-RMU M1ruSmZ2dmO2aX;uJIF{e2G7 NELwSYMyOCEQvF2= MYTEUXNQ MWPpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHL5JJVxemWpdXzheIlwdiCxZjDwNlE> M2jiTFI1QTB4MUO3
Mel-JD NUn6c4JRTnWwY4Tpc44h[XO|YYm= MXuxNEDPxE1? NIPrcWpFVVOR MmjDbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDifUB2eHKnZ4XsZZRqd25ib3[gdFIy NXPVTlhWOjR7ME[xN|c>
Mel-RM NIHrUolHfW6ldHnvckBie3OjeR?= M2fydlExKM7:TR?= MVvEUXNQ Mn32bY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDifUB2eHKnZ4XsZZRqd25ib3[gdFIy MWiyOFkxPjF|Nx?=
Me007 M1TRTmZ2dmO2aX;uJIF{e2G7 MnzpNVAh|ryP NVH0eG5oTE2VTx?= NXWwO4ZvfXC{ZXf1cIF1\XNicILvZZBweHSxdHnjJIFv\CClZXzsJIN6[2ynIHHydoV{fCCpZX7ldy=> MXmyOFkxPjF|Nx?=
SK-Mel-28 Mn65SpVv[3Srb36gZZN{[Xl? Ml6xNVAh|ryP NUnTN2ZzTE2VTx?= M4LlTJVxemWpdXzheIV{KHC{b3Hwc5B1d3SrYzDhcoQh[2WubDDjfYNt\SCjcoLld5Qh\2WwZYO= NYXTWG1EOjR7ME[xN|c>
Mel-RMU M2SwOmZ2dmO2aX;uJIF{e2G7 M4rBc|ExKM7:TR?= NEX3V3JFVVOR MVP1dJJm\3WuYYTld{Bxem:jcH;weI91cWNiYX7kJINmdGxiY4njcIUh[XK{ZYP0JIdmdmW| M4Hib|I1QTB4MUO3
Mel-JD NIPYfJRHfW6ldHnvckBie3OjeR?= MYWxNEDPxE1? MlHFSG1UVw>? MnK0eZBz\We3bHH0[ZMheHKxYYDvdJRwfGmlIHHu[EBk\WyuIHP5Z4xmKGG{cnXzeEBo\W6ncx?= NXTrXHpuOjR7ME[xN|c>
Mel-RM NF\jcFVHfW6ldHnvckBie3OjeR?= NEDqXVAyOCEQvF2= NYG2WGJJTE2VTx?= M3nhU5VxemWpdXzheIV{KHC{b3Hwc5B1d3SrYzDhcoQh[2WubDDjfYNt\SCjcoLld5Qh\2WwZYO= Mm[4NlQ6ODZzM{e=

... Click to View More Cell Line Experimental Data

In vivo Administration of I-BET151 at 30 mg/kg/day significantly inhibits tumor growth of murine MLL-AF9 and human MLL-AF4 leukaemia in mice, and provides marked survival benefit. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Fluorescence anisotropy (FP) ligand displacement assay:

All components are dissolved in buffer of composition 50 mM HEPES pH 7.4, 150 mM NaCl and 0.5 mM CHAPS with final concentrations of BRD 2/3/4 75 nM, fluorescent ligand 5 nM. 10 μL of this reaction mixture is added using a micro multidrop to wells containing 100 nL of various concentrations of I-BET151 or DMSO vehicle (1% final) in Greiner 384 well Black low volume microtitre plate and equilibrated in the dark for 60 minutes at room temperature. Fluorescence anisotropy is read in Envision (lex = 485 nm, lEM = 530 nm; Dichroic = 505 nM).
Cell Research:

[1]

+ Expand
  • Cell lines: MV4;11, MOLM13, NOMO1, RS4;11, HEL, HL60 and K562
  • Concentrations: Dissolved in DMSO, final concentrations ~100 μM
  • Incubation Time: 24, or 72 hours
  • Method:

    Cells are exposed to various concentrations of I-BET151 for 24 or 72 hours in 384-well or 96-well plates. For cell growth inhibition assays, plates are added with CellTiter-Glo reagent using a volume equivalent to the cell culture volume in the wells, shaken for approximately 2 minutes and chemiluminescent signal is read on the Analyst GT or EnVision Plate Reader. For cell proliferation assays, CellTiter-Aqueous One is added to each well and plates are incubated for 4 hours at 37 °C. Absorbance is read at 490 nm on a SpectraMax Gemini reader


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: NOD-SCID mice injected intravenously with MV4;11 cells, and C57BL/6 mice injected intravenously with MLL-AF9 cells
  • Formulation: Dissolved in normal saline containing 5% (v/v) DMSO and 10% (w/v) Kleptose HPB
  • Dosages: ~30 mg/kg/day
  • Administration: Intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro Ethanol 27 mg/mL (64.99 mM)
DMSO Insoluble
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 415.44
Formula

C23H21N5O3

CAS No. 1300031-49-5
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: buy I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) supplier | purchase I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) cost | I-BET151 (GSK1210151A) manufacturer | order I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID